Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Proof of Mechanism Study With GSK2126458 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01725139
Recruitment Status : Completed
First Posted : November 12, 2012
Last Update Posted : November 21, 2019
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Completed
Actual Primary Completion Date : July 12, 2016
Actual Study Completion Date : July 12, 2016
Publications:
P T Lukey, S Harrison, S Yang, Y Man, B F Holman, A Rashidnasab, G Azzopardi, M Grayer, J K Simpson, P Bareille, L Paul, H Woodcock, R Toshner, P Saunders, P L Molyneaux, K Thielemans, F J Wilson, P F Mercer, R C Chambers, A M Groves, W A Fahy, R P Marshall, T M Maher. RESUBMISSION of Pi3KPAN-1MS-00026641 A Randomised, Placebo-Controlled Study of Omipalisib (PI3K/mTOR) in Idiopathic Pulmonary Fibrosis. Eur Respir J. 2019;53(2)

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):